Challenges in Drug Development
Considerable challenges in drug development, particularly in the face of further organizational changes slated for OGD. A range of legislative and regulatory actions have facilitated consumer access to safe, high-quality generic products, although manufacturing lapses and product quality problems have created critical shortages in important medicines, casting a shadow over the industry's success.
In 2012 the global market for drug development and services reached $3.5 billion. This market is reached $4.5 billion in 2013 and expected to reach 11.7 billion in 2018, a compound annual growth rate (CAGR) of 21.2%.
- Phase zero trials
- Mechanism
- Drug delivery essentials towards better bioavailability
Related Conference of Challenges in Drug Development
Challenges in Drug Development Conference Speakers
Recommended Sessions
- Advances in BABE
- Assessment of Bioequivalence
- BA/BE of Biologics & Biosimilars
- Bioavailability Studies
- Bioequivalence Protocols : In vivo/ In vitro studies
- Bioequivalence Studies
- Challenges in Drug Design
- Challenges in Drug Development
- Clinical Pharmacology and Therapeutics
- Clinical Trials
- Contract Research Organizations
- Factors Affecting Bioavailability
- Managing BA/BE Studies
- Nutrient Bioavailability
- Pharma Clinical Trials
- Pharmaceutical Industry: Entrepreneurs Investment Meet
- Regulatory Requirements for Bioequivalence
- Significance of BA/BE Studies
- Study Designs